Session » Vasculitis – ANCA-Associated Poster

Date: Sunday, November 8, 2020

Time: 9:00AM-11:00AM

Meeting: ACR Convergence 2020

9:00AM-11:00AM: Abstract Number: 1429

An Evaluation of Real World Use of Biologics in Rare Systemic Vasculitides During Routine Clinical Care in the US

9:00AM-11:00AM: Abstract Number: 1427

Anti-IL5 Therapy for Eosinophilic Granulomatosis with Polyangiitis (EGPA) – An 18 Month Follow-up Study as a Steroid Sparing Therapeutic Approach

9:00AM-11:00AM: Abstract Number: 1420

Characterization of ANCA-Associated Vasculitis Among African American Patients

9:00AM-11:00AM: Abstract Number: 1419

Clinical Disease Might Be Divided into Two Phenotypes in ANCA Associated Vasculitis; Results of a Cluster Analysis

9:00AM-11:00AM: Abstract Number: 1421

Clinical Features, Disease Activity and Prognosis of ANCA-Associated Vasculitis in US African Americans

9:00AM-11:00AM: Abstract Number: 1418

Clinical Presentations and Follow-up Results of Granulomatosis with Polyangiitis: An Analysis of 8 Years Clinical Experience with 220 Patients from a National Referral Center

9:00AM-11:00AM: Abstract Number: 1423

Declining In-Hospital Mortality in Vasculitis: A 17-year U.S. National Study

9:00AM-11:00AM: Abstract Number: 1416

Effects of the COVID-19 Pandemic on Patients Living with Vasculitis

9:00AM-11:00AM: Abstract Number: 1422

Healthcare Utilization Among Patients Diagnosed with ANCA-Associated Vasculitis Between 2007 and 2014 in a Multi-Center Cohort Linked to Medicare Claims Data

9:00AM-11:00AM: Abstract Number: 1436

Incidence Rate, Predictors and Outcome of Stroke in Patients with ANCA Associated Vasculitis – A Population-based Study

9:00AM-11:00AM: Abstract Number: 1431

Interstitial Lung Disease in Patients with ANCA Associated Vasculitis – a Prospective Single Centre Study

9:00AM-11:00AM: Abstract Number: 1437

Measuring Disease Activity and Functional Status in Patients with Granulomatosis with Polyangiitis (Wegener’s) (GPA)

9:00AM-11:00AM: Abstract Number: 1424

Outcomes of Hospitalizations for Acute Myocardial Infarction in Patients with ANCA Associated Vasculitis from the National Inpatient Sample

9:00AM-11:00AM: Abstract Number: 1426

Prevalence of ANCA-associated Vasculitis and Spatial Association with Quarries in a French Northeast Region: A Capture-recapture and Geospatial Analysis

9:00AM-11:00AM: Abstract Number: 1435

Prognostic Factors for Mononeuritis Multiplex Associated with ANCA-associated Vasculitis

9:00AM-11:00AM: Abstract Number: 1439

Proteinase 3-Reactive B Cell Pool Restructuring After Rituximab and Risk of Relapse in Severe PR3-ANCA-Associated Vasculitis

9:00AM-11:00AM: Abstract Number: 1425

Reduced Risk of Cardiovascular Diseases Events with Renal Transplantation in Granulomatosis with Polyangiitis in the United States: Data from the US Renal Data System

9:00AM-11:00AM: Abstract Number: 1417

Risk of Relapse of ANCA-associated Vasculitis in Patients of 75 Years and Older: A Retrospective Study

9:00AM-11:00AM: Abstract Number: 1438

Rituximab Immunogenicity in ANCA-associated Vasculitis (RITUXIMAV)

9:00AM-11:00AM: Abstract Number: 1428

The Efficacy and Safety of Tocilizumab in Patients with Giant Cell Arteritis: A Systematic Review and Meta-Analysis

9:00AM-11:00AM: Abstract Number: 1440

The Myeloperoxidase (MPO) Anti-Neutrophilic Cytoplasmic Antibody (ANCA) Binding Epitope, MPO447-459 Induces CD4 T-cell Proliferation in Patients with MPO-ANCA-associated Vasculitis

9:00AM-11:00AM: Abstract Number: 1430

The Role of Lung Biopsy in Pediatric ANCA-associated Vasculitis

9:00AM-11:00AM: Abstract Number: 1434

The Role of Sural Nerve Biopsy in the Diagnosis of Systemic Vasculitis – a Retrospective Study from Two Specialized Centres

9:00AM-11:00AM: Abstract Number: 1433

Thyroid Disease in ANCA-associated Vasculitis. a Population-based Study

9:00AM-11:00AM: Abstract Number: 1432

Thyroid Disease in Patients with ANCA-Associated Vasculitis

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].